Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Original Article

Volume 9, Number 5, October 2019, pages 159-164


Effects of Anti-Malarial Drug, Hydroxychloroquine, on Glucose and Lipid Metabolism in Japanese Population

Figure

Figure 1.
Figure 1. The recruitment of studied subjects.

Tables

Table 1. Clinical Data at Baseline (n = 26)
 
SD: standard deviation.
Anthropometric data
  Sex (female, n (%))22 (84.6%)
  Age (years, mean ± SD)46 ± 16
  Body height (cm, mean ± SD)159.9 ± 6.3
  Body weight (kg, mean ± SD)51.8 ± 4.6
  Body mass index (kg/m2, mean ± SD)20.8 ± 2.4
Rheumatic diseases
  Systemic lupus erythematosus (n (%))22 (84.6%)
  Rheumatoid arthritis (n (%))4 (15.4%)
Metabolic diseases
  Diabetes (n (%))3 (11.5%)
  Dyslipidemia (n (%))7 (26.9%)

 

Table 2. Daily Dose of Hydroxychloroquine and Other Medication at Baseline
 
SD: standard deviation.
Daily dose of hydroxychloroquine (mg, mean ± SD)284.6 ± 67.5
For rheumatic diseases
  Prednisolone
    Patients who had taken prednisolone (n (%))23 (88.5%)
    Daily dose (mg)6.5 ± 3.5
  Immunosuppressants (n (%))7 (26.9%)
For diabetes
  Oral anti-diabetic drugs (n (%))2 (7.7%)
  Insulin (n (%))0 (0%)
For dyslipidemia
  Statin (n (%))6 (23.1%)
  Fibrate (n (%))2 (7.7%)

 

Table 3. Change of HbA1c After the Start of Hydroxychloroquine
 
MonthnValues at baselineValues after hydroxychloroquine useP value
HbA1c: hemoglobin A1c.
1115.91 ± 0.605.87 ± 0.540.397
2115.83 ± 0.595.75 ± 0.480.221
3106.02 ± 0.505.92 ± 0.440.348
4115.88 ± 0.625.74 ± 0.550.202
575.99 ± 0.575.74 ± 0.410.075
695.91 ± 0.695.66 ± 0.470.048
786.01 ± 0.555.76 ± 0.320.154
875.73 ± 0.725.50 ± 0.510.331
975.86 ± 0.775.71 ± 0.500.441
1065.80 ± 0.765.52 ± 0.500.164
1175.97 ± 0.645.70 ± 0.460.184

 

Table 4. Change of Serum Triglyceride (mg/dL) After the Start of Hydroxychloroquine
 
MonthnValues at baselineValues after hydroxychloroquine useP value
112101.0 ± 27.193.7 ± 26.80.005
210102.3 ± 27.999.3 ± 30.50.657
311102.6 ± 21.790.1 ± 24.50.011
41399.2 ± 25.796.2 ± 32.50.618
510101.8 ± 19.796.5 ± 16.20.228
6988.1 ± 20.781.7 ± 20.60.318
79105.2 ± 22.888.8 ± 17.60.006
8898.0 ± 28.781.5 ± 24.10.045
9993.2 ± 25.288.0 ± 18.80.438
10997.2 ± 27.095.0 ± 30.50.876
119104.1 ± 22.287.6 ± 17.20.022

 

Table 5. Change of Serum HDL-C (mg/dL) After the Start of Hydroxychloroquine
 
MonthnValues at baselineValues after hydroxychloroquine useP value
HDL-C: high-density lipoprotein-cholesterol.
11359.5 ± 22.959.1 ± 21.50.722
21159.2 ± 24.557.8 ± 24.40.393
31261.2 ± 23.261.0 ± 23.00.908
41458.2 ± 21.360.4 ± 21.70.104
51060.7 ± 23.663.3 ± 21.80.164
61061.6 ± 22.459.1 ± 24.40.231
71066.4 ± 21.864.9 ± 20.90.696
8862.9 ± 24.562.8 ± 22.90.955
91063.2 ± 22.967.5 ± 21.60.217
101061.8 ± 22.565.4 ± 22.90.287
111065.3 ± 21.165.7 ± 22.50.846

 

Table 6. Change of Serum LDL-C (mg/dL) After the Start of Hydroxychloroquine
 
MonthnValues at baselineValues after hydroxychloroquine useP value
LDL-C: low-density lipoprotein-cholesterol.
114157.4 ± 102.6141.5 ± 138.00.382
213179.9 ± 100.3134.8 ± 68.10.009
313143.2 ± 64.6131.7 ± 58.10.373
416173.9 ± 101.5149.6 ± 128.10.133
510151.0 ± 75.2115.9 ± 47.20.132
612190.8 ± 106.5176.8 ± 127.10.551
711133.1 ± 65.9101.5 ± 37.30.099
89182.9 ± 132.5158.1 ± 125.10.291
912180.8 ± 108.7155.6 ± 95.50.558
1011180.3 ± 120.3134.0 ± 52.30.098
1111141.8 ± 69.8125.4 ± 70.70.392

 

Table 7. Change of Serum Non-HDL-C (mg/dL) After the Start of Hydroxychloroquine
 
MonthnValues at baselineValues after hydroxychloroquine useP value
HDL-C: high-density lipoprotein-cholesterol.
113135.2 ± 26.9120.8 ± 20.20.051
211143.3 ± 22.8127.8 ± 27.40.038
312132.7 ± 28.3119.0 ± 23.90.008
414133.7 ± 26.0126.5 ± 24.30.157
59131.4 ± 25.9119.8 ± 17.60.074
610127.8 ± 24.2122.4 ± 22.20.579
710134.0 ± 29.1111.7 ± 15.10.011
88129.5 ± 26.2115.9 ± 18.40.202
910131.9 ± 26.6122.7 ± 19.20.278
1010133.2 ± 24.9124.5 ± 25.70.361
1110133.0 ± 28.1120.8 ± 23.60.164